MercoPress6h
Uruguay reports first autochthonous case of dengue
Uruguayan health authorities Monday confirmed the first autochthonous case of dengue this year. It was a patient in ...
dvm3604h
Understanding and combating heartworm preventive resistance
Lindsay Starkey, DVM, PhD, DACVM (Parasitology), shares more on the current state of heartworm preventive resistance in ...
CURE11h
Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...
PipelineReview.com10h
SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
BEIJING, China I March 24, 2025 I SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for ...
TMCnet14h
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer. Initiation of trial sites underway for ground ...
Le Lézard11h
Next Generation Cybersecurity Tools Accelerate Discovery and Remediation of Critical Medical Device Vulnerabilities
New security analysis tools have led to the discovery of critical vulnerabilities in widely-deployed hospital patient monitoring devices used for tracking vital signs and providing life-saving care.